Group 1 - Catalyst Pharmaceutical (CPRX) reported revenue of $152.61 million for the quarter ended December 2025, reflecting a 7.6% increase year-over-year and a 9% surprise over the Zacks Consensus Estimate of $140.02 million [1] - The earnings per share (EPS) for the quarter was $0.68, down from $0.70 in the same quarter last year, with a significant EPS surprise of +60.95% compared to the consensus estimate of $0.42 [1] - The stock has returned +2.7% over the past month, outperforming the Zacks S&P 500 composite's +0.6% change, and currently holds a Zacks Rank 3 (Hold) [3] Group 2 - Product revenue net for the quarter was $152.5 million, exceeding the average estimate of $140.01 million from four analysts, marking a year-over-year change of +7.5% [4] - FIRDAPSE generated $97.62 million in revenue, surpassing the estimated $96.43 million, representing an 18.3% increase year-over-year [4] - AGAMREE revenue reached $35.3 million, exceeding the average estimate of $31.3 million, with a year-over-year change of +67.5% [4] - FYCOMPA reported revenue of $19.58 million, compared to the average estimate of $12.28 million, indicating a year-over-year decline of -48.8% [4] - License and other revenues were $0.11 million, significantly higher than the estimated $0.03 million, reflecting a remarkable +909.1% change year-over-year [4]

Core Insights - Catalyst Pharmaceuticals achieved record revenues of $589 million in 2025, reflecting a 20.3% growth in net product revenue driven by enhanced patient identification and market penetration [4] - FIRDAPSE's growth was supported by a 40% increase in identified patient leads and a 12% reduction in early discontinuations due to a new pharmacy outreach program [4] - AGAMREE reached 100% penetration in top Centers of Excellence, capturing 80% of the Duchenne Muscular Dystrophy patient population [4] - The company plans to transition FYCOMPA to a non-promoted status following generic entry while still contributing to revenue [4] - Business development activity surged with over 100 assessments in 2025, with 90% being inbound inquiries [4] Strategic Performance and Operational Drivers - The company attributes its commercial success to a 'plug-and-play' infrastructure utilizing AI and machine learning to prioritize high-urgency patient leads [4] - Total revenue guidance for 2026 is set between $615 million and $645 million, assuming continued expansion in idiopathic and cancer-associated LEMS markets [4] - The strategy for FIRDAPSE in 2026 includes integrating updated NCCN guidelines into oncology care pathways to tap into the under-penetrated cancer-associated LEMS segment [4] - AGAMREE's growth is expected to deepen within existing Centers of Excellence, supported by a 5-year SUMMIT follow-up study [4] Financial Outlook - A $12.5 million milestone payment was triggered in Q4 2025 as AGAMREE's net product revenue surpassed the $100 million threshold [6] - R&D expenses are forecasted to rise to $17.5 million - $22.5 million in 2026 to support AGAMREE life cycle management and new indication assessments [6] - FYCOMPA revenue is expected to decline significantly, with 2026 guidance set at $40 million to $45 million following the cessation of active promotion [4] Legal Considerations - A patent infringement trial against Hetero USA is scheduled for March 23, 2026, to protect FIRDAPSE's intellectual property ahead of the 30-month stay expiration [4]

Core Insights - Catalyst Pharmaceuticals reported total revenues of $589.0 million for the full year 2025, reflecting a year-over-year growth of 19.8% and marking a record year for the company [1][8] - The company expects total revenues for 2026 to be between $615 million and $645 million, indicating confidence in the continued growth of its products, FIRDAPSE and AGAMREE [1][18] Financial Performance - Full year 2025 product revenue was $588.8 million, a 20.3% increase from $489.3 million in 2024 [3] - FIRDAPSE product revenue for 2025 was $358.4 million, up 17.1% from the previous year, while AGAMREE product revenue surged by 154.3% to $117.1 million [3][7] - GAAP net income for 2025 was $214.3 million, representing a 30.8% increase from $163.9 million in 2024 [3][13] - Non-GAAP net income for 2025 was $346.2 million, a 25.3% increase from $276.3 million in 2024 [3][14] Fourth Quarter Highlights - Total revenues for Q4 2025 were $152.6 million, a 7.6% increase from $141.8 million in Q4 2024 [8][12] - FIRDAPSE revenue in Q4 2025 was $97.6 million, an 18.3% increase year-over-year, while AGAMREE revenue reached $35.3 million, reflecting a 67.5% increase [7][12] Business Strategy and Development - The company is focusing on lifecycle management opportunities and expanding its business development strategy to include products in development with established proof of concept [2] - Catalyst reviewed over 100 prospective clinical stage acquisition targets in 2025, aiming to identify rare disease assets that address unmet medical needs [7] Future Outlook - For 2026, FIRDAPSE's revenue is expected to be between $435 million and $450 million, indicating growth of 21.4% to 25.6% compared to 2025 [18] - AGAMREE's revenue for 2026 is projected to be between $140 million and $150 million, reflecting continued market adoption [19] - FYCOMPA's revenue for 2026 is expected to be between $40 million and $45 million, despite the loss of patent exclusivity [20] Recognition and Awards - Catalyst Pharmaceuticals was recognized in the Deloitte Technology Fast 500™ as one of North America's Fastest-Growing Companies and ranked 11th on Forbes' 2026 list of America's Most Successful Small-Cap Companies [16]

Core Insights - Analysts project Catalyst Pharmaceutical (CPRX) will report quarterly earnings of $0.42 per share, reflecting a 40% decline year over year [1] - Revenue estimates for the quarter are set at $140.02 million, indicating a 1.3% decrease from the same period last year [1] - There have been no revisions in the consensus EPS estimate over the last 30 days, suggesting stability in analysts' forecasts [1] Revenue Projections - Analysts expect 'Revenues- Product revenue, Net- FIRDAPSE' to be $96.43 million, representing a year-over-year increase of 16.9% [4] - The consensus for 'Revenues- Product revenue, Net- FYCOMPA' is $12.28 million, indicating a significant decline of 67.9% year over year [4] - For 'Revenues- Product revenue, Net- AGAMREE', analysts project $31.30 million, reflecting a year-over-year increase of 48.5% [4] Overall Performance - The average prediction for 'Revenues- Product revenue, net' stands at $140.01 million, showing a year-over-year change of -1.3% [5] - Over the past month, Catalyst shares have gained 0.5%, while the Zacks S&P 500 composite has decreased by 1% [5] - Catalyst holds a Zacks Rank of 3 (Hold), suggesting its performance is expected to align with the overall market in the near term [5]

NASDAQ: CPRX January 2026 Improving the Lives of Patients Living with Rare Diseases Safe Harbor This presentation contains forward-looking statements that are subject to a number of risks and uncertainties, many of which are outside our control. All statements regarding our strategy, future operations, financial position, estimated revenues or losses, projected costs, prospects, plans, and objectives, other than statements of historical fact included in our filings with the U.S. Securities and Exchange Comm ...

Overview of Catalyst - Catalyst focuses on orphan and rare diseases with three product candidates [1] - The first product, FIRDAPSE, has been on the market since 2019 and is used for Lambert-Eaton myasthenic syndrome, both idiopathic and cancer-associated [1] Product Candidates - The second product, FYCOMPA, is for epilepsy, which is not classified as a rare disease; however, its acquisition has benefited the company [2] - FYCOMPA's solid dose lost patent protection in late May, leading to some market competition, but the product has still overperformed [2]

Financial Data and Key Metrics Changes - Catalyst Pharmaceuticals reported total revenue of $148.4 million for Q3 2025, a 15.3% increase year over year from $128.7 million in Q3 2024 [4][21] - Net income before income taxes for Q3 2025 was $71.0 million, reflecting a 24.2% increase compared to $57.2 million in Q3 2024 [22] - GAAP net income for Q3 2025 was $52.8 million, or $0.42 per diluted share, up 20.3% from $43.9 million, or $0.35 per diluted share in Q3 2024 [22] - Non-GAAP net income for Q3 2025 was $86.1 million, or $0.68 per diluted share, compared to $71.1 million, or $0.57 per diluted share in Q3 2024 [23] - The company ended Q3 2025 with a cash position of $689.9 million and no debt, an increase from $517.6 million at the end of 2024 [5][26] Business Line Data and Key Metrics Changes - Firdapse generated revenue of $92.2 million in Q3 2025, a 16.2% increase year over year [6][14] - AGAMREE achieved net product revenue of $32.4 million in Q3 2025, a 115.2% increase from Q3 2024 [8][18] - FYCOMPA reported revenue of $23.8 million in Q3 2025, a decrease of 25.8% year over year due to generic competition [9][19] Market Data and Key Metrics Changes - The company raised its total revenue guidance for 2025 to between $565 million and $585 million, reflecting strong performance across its product lines [5][20] - Firdapse's full-year net product revenue guidance was maintained at between $355 million and $360 million [8][15] - AGAMREE's full-year net product revenue guidance was raised to between $105 million and $115 million [9][19] Company Strategy and Development Direction - Catalyst Pharmaceuticals is focused on expanding its market presence in both idiopathic and cancer-associated LEMS, with a strong emphasis on patient identification and education [7][16] - The company is actively pursuing business development opportunities and evaluating a broad range of potential acquisitions [12] - Catalyst Pathways, a personalized treatment support program, is a key differentiator in enhancing patient engagement and adherence [10][11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term outlook, citing strong demand for rare disease therapies and operational excellence [4][5] - The company anticipates continued growth momentum into 2026, particularly for Firdapse and AGAMREE [8][17] - Management acknowledged the challenges posed by generic competition but remains optimistic about brand loyalty for FYCOMPA [19][33] Other Important Information - Catalyst announced a new share buyback program to repurchase up to $200 million of its common stock [5] - The company is committed to defending its intellectual property, with ongoing litigation against Hetero USA Incorporated set for trial in March 2026 [13][86] Q&A Session Summary Question: Insights on Firdapse's oncology efforts and Fycompa's brand loyalty - Management indicated that they are in the early stages of penetrating the oncology market for LEMS and will provide updates in future quarters [30][31] - Regarding Fycompa, management noted that brand loyalty remains strong, but they expect some revenue erosion as more generics enter the market [33][34] Question: Adoption of NCCN guidelines and Fycompa's stickiness - Management stated that the adoption of updated NCCN guidelines is more of a 2026 story, with ongoing efforts to educate oncology practices [41][42] - The stickiness of Fycompa is attributed to patient reluctance to switch medications, especially for anti-seizure treatments [38][39] Question: AGAMREE prescriber base and lifecycle management opportunities - Management reported strong adoption of AGAMREE across key treatment centers, with ongoing efforts to deepen prescribing [45][46] - Lifecycle management opportunities for AGAMREE are being evaluated, focusing on rare therapeutic areas [47][48] Question: Firdapse growth drivers and guidance rationale - Management highlighted that growth for Firdapse will come from both idiopathic and cancer-associated LEMS, with strong new patient enrollments [62][63] - The decision to maintain guidance rather than raise it reflects a cautious approach, anticipating potential seasonality in Q4 [67][68]

Core Insights - Catalyst Pharmaceutical (CPRX) reported $148.39 million in revenue for Q3 2025, marking a year-over-year increase of 15.3% and exceeding the Zacks Consensus Estimate by 8.77% [1] - The earnings per share (EPS) for the quarter was $0.68, up from $0.57 a year ago, representing a surprise of 33.33% over the consensus estimate of $0.51 [1] Revenue Breakdown - Product revenue from FIRDAPSE was $92.18 million, slightly above the average estimate of $91.78 million, reflecting a year-over-year increase of 16.2% [4] - Product revenue from FYCOMPA was reported at $23.8 million, significantly higher than the estimated $15.16 million, but this represents a decline of 25.8% compared to the previous year [4] - Product revenue from AGAMREE reached $32.38 million, surpassing the average estimate of $29.47 million, with a substantial year-over-year increase of 115.2% [4] - Total product revenue netted $148.37 million, exceeding the average estimate of $136.41 million, and showing a year-over-year growth of 17.4% [4] - License and other revenues were reported at $0.03 million, slightly above the average estimate of $0.02 million [4] Stock Performance - Catalyst's shares have returned +2.5% over the past month, outperforming the Zacks S&P 500 composite, which saw a +1% change [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market in the near term [3]

Core Insights - Catalyst Pharmaceuticals reported Q3 2025 total revenues of $148.4 million, a 17.4% increase from Q3 2024, driven by growth in FIRDAPSE®, AGAMREE®, and continued demand for FYCOMPA® [1][5][9] - The company raised its full-year 2025 total revenue guidance to between $565 million and $585 million, reflecting better-than-expected performance [1][5] - A share repurchase program of up to $200 million was announced, indicating confidence in the company's long-term outlook [1][7] Financial Performance - Q3 2025 net product revenues reached $148.4 million, up from $126.4 million in Q3 2024, marking a 17.4% increase [5][9] - FIRDAPSE net product revenue for Q3 2025 was $92.2 million, a 16.2% increase compared to Q3 2024 [5][11] - AGAMREE net product revenue for Q3 2025 was $32.4 million, reflecting a 115.2% increase year-over-year [5][6] - FYCOMPA net product revenue for Q3 2025 was $23.8 million, a 25.8% decrease from Q3 2024 due to generic competition [5][6] Income and Expenses - GAAP net income for Q3 2025 was $52.8 million, a 20.3% increase from $43.9 million in Q3 2024 [11][24] - Non-GAAP net income for Q3 2025 was $86.1 million, up from $71.1 million in Q3 2024, representing a 21.2% increase [12][24] - Research and development expenses for Q3 2025 were $2.7 million, down from $3.3 million in Q3 2024 [10][21] - Selling, general and administrative expenses for Q3 2025 were $47.5 million, compared to $45.9 million in Q3 2024 [10][21] Cash Position - Cash and cash equivalents as of September 30, 2025, were $689.9 million, a 33.3% increase from $517.6 million at the end of 2024 [13][26] Strategic Developments - Catalyst announced the settlement of FIRDAPSE patent litigation with Lupin, allowing Lupin to market a generic version starting February 2035 [7] - The company is actively enrolling patients in the SUMMIT study for AGAMREE, aimed at evaluating its long-term clinical safety profile [5][7] - Catalyst has been recognized as one of the BioSpace 2026 Best Places to Work, ranking 13th among small companies in the U.S. [8]

Summary of Catalyst Pharmaceuticals (CPRX) 2025 Conference Call Company Overview - Catalyst Pharmaceuticals operates under a buy-and-build business model, focusing on orphan and rare diseases, particularly in the CNS (Central Nervous System) sector. This model aims to reduce risk for shareholders and stakeholders by leveraging valuable assets and established infrastructure for patient support and commercial operations [4][5] Key Products and Market Focus - The company has three main assets: - **FIRDAPSE**: For Lambert-Eaton Myasthenic Syndrome (LEMS) with an estimated patient population of 2,500 to 3,000 in the U.S. - **AGAMREE**: A novel corticosteroid for Duchenne muscular dystrophy (DMD) with a patient population of 11,000 to 13,000, launched last year. - **FYCOMPA**: An epilepsy drug recently lost exclusivity, with guidance for 2025 set at $90 to $95 million [6][15][29] Performance Highlights - FIRDAPSE is performing well, with initiatives to improve patient titration and support from specialty pharmacies. The average physician sees one LEMS patient in their career, indicating a need for enhanced education and support [10][11] - AGAMREE is gaining traction, with 45% of patients coming from Influenza treatments and 45% from prednisone, indicating a broad market engagement [46][47] - FYCOMPA's performance is under scrutiny due to the introduction of generics, with expectations of a softer second half of the year [15][16] Growth Potential - FIRDAPSE has a total addressable market estimated at $1.2 billion, with current penetration at 30% for idiopathic LEMS and less than 10% for cancer-associated LEMS. The company sees significant growth opportunities in oncology due to recent guideline changes and testing accessibility [19][34] - AGAMREE's market share is expected to grow as it captures patients transitioning from other steroid treatments, with a focus on pediatric applications [68] Intellectual Property (IP) Status - Catalyst has settled with three out of four generic filers for FIRDAPSE, extending the entry date for generics to February 2035. The remaining litigant is under ongoing discussions [23][24] Business Development Strategy - The company is actively seeking differentiated products under $500 million, focusing on orphan drugs with potential for multiple indications. There is a particular interest in pediatric opportunities and oncology [66][68] Key Value Drivers - Enrollment in the Summit study, which aims to evaluate safety signals for AGAMREE, is crucial for future growth. The prevalence of testing for LEMS is also a significant indirect measure of the company's success [69] Conclusion - Catalyst Pharmaceuticals is positioned for growth in the orphan drug market, with a strong focus on patient support and education. The company is optimistic about its product pipeline and market opportunities, particularly in oncology and pediatric applications, while navigating challenges posed by generics in the epilepsy market [4][68]